CRISPR Therapeutics vs X4 Pharmaceuticals
CRSP and XFOR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CRSP and XFOR compare
CRISPR Therapeutics is the larger company, worth 13 times as much as X4 Pharmaceuticals ($4.1B against $309M).
X4 Pharmaceuticals grew revenue faster over the last twelve months (73.7% versus −34.3% for CRISPR Therapeutics).
X4 Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −813% compared with −1812% at CRISPR Therapeutics.
CRISPR Therapeutics scores higher on the StockData Score (8 against 3 for X4 Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CRSP | XFOR |
|---|---|---|
| Size and price | ||
| Market cap | $4.1B | $309M |
| Share price | $42.24 | $3.12 |
| Change, 1 year | −19.1% | −19.4% |
| Change, 5 years | −48.8% | −97.8% |
| Beta (5Y) | 1.38 | 1.41 |
| Employees | 393 | 45 |
| StockData Score | ||
| Total score | 8 (better) | 3 |
| Valuation score | 0 | 0 |
| Growth score | 1 | 2 (better) |
| Performance score | 2 (better) | 0 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 162× | 31.2× (better) |
| P/B | 2.5× | 2.2× (better) |
| FCF yield | −9.2% | – |
| Growth | ||
| Revenue growth (TTM) | −34.3% | 73.7% (better) |
| Revenue growth, 5Y average | 37.3% (better) | 16.7% |
| Profitability | ||
| Gross margin | – | 68.8% |
| Operating margin | −2115% | −812% (better) |
| Net margin | −1812% | −813% (better) |
| FCF margin | −1497% | – |
| Return on equity | −25.6% (better) | −80.3% |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −9.3× |
| Current ratio | 16.21 (better) | 13.22 |
| Altman Z-score | 1.78 (better) | −2.09 |
| Piotroski F-score | 2 | 4 (better) |
| Dividends and buybacks | ||
| Buyback yield | −2.7% | – |
| Shareholder yield | −2.7% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 78.9% | 103% |
| Held by insiders | 2.7% | 12.2% |
| Insider net buying, 12 months | −$17.9M | −$451K (better) |
| Short interest, % of float | 18.3% | 9.2% |
Go deeper
- CRSP stock overview
- CRSP income statement
- CRSP valuation and score
- XFOR stock overview
- XFOR income statement
- XFOR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.